Obesity Association publishes 2026 pharmacologic treatment standards ranking every approved drug

The Obesity Association, a division of the American Diabetes Association, published "Pharmacologic Treatment of Obesity in Adults" on January 13, 2026, the newest section of its Standards of Care in Overweight and Obesity ^[1][3]. The 23-page document appears in the inaugural edition of Diabetes, Obesity, and Cardiometabolic CARE and in BMJ Open Diabetes Research & Care ^[1][3].

The headline change is how directly it endorses drug treatment. For adults with obesity who are at high risk of, or already have, obesity-related diseases and complications, the standards say clinicians should offer obesity medications as part of an initial treatment plan — not only after lifestyle changes fail ^[1][2]. For adults with obesity and no related complications, medications should be considered as part of the plan to promote weight reduction, prevent further weight gain, and lower the risk of future disease ^[1][2].

The numbers behind the targets

The guideline sets tiered weight-reduction goals rather than one number. At least 5% of starting body weight is the baseline goal for all adults treated with obesity medications, which the authors say delivers clinically meaningful improvements in cardiometabolic measures ^[2][3]. At least 10% is recommended to manage complications such as MASH, heart failure with preserved ejection fraction, and knee osteoarthritis ^[2]. Emerging data suggest at least 15% may be needed in some cases, particularly moderate-to-severe obstructive sleep apnea ^[2]. A 10% to 15% loss produced better glucose, blood pressure, and lipid results than a 5% to 10% loss ^[3]. Goals should be incremental and re-evaluated roughly every three months ^[2].

Drug choice is then mapped to the condition being treated. For prediabetes, hypertension, and type 2 diabetes, tirzepatide (Mounjaro/Zepbound) and semaglutide (Ozempic/Wegovy/Rybelsus) are listed as having demonstrated benefit, with liraglutide also listed for type 2 diabetes and orlistat for blood pressure ^[2]. Semaglutide is the drug with demonstrated benefit for atherosclerotic cardiovascular disease, HFpEF, and MASH with moderate or advanced fibrosis ^[2]. Tirzepatide is the drug with demonstrated benefit for moderate-to-severe sleep apnea ^[2]. Phentermine-topiramate, naltrexone-bupropion, liraglutide, and orlistat appear mostly in the "potential benefit" column across these conditions ^[2]. For moderate osteoarthritis, no drug has demonstrated benefit; semaglutide, tirzepatide, and liraglutide are listed as potential ^[2]. The published sources here do not display the guideline's letter evidence grades, and orforglipron (Foundayo) does not appear in the summarized tables ^[2].

Other recommendations

The standards say obesity medications should only be prescribed alongside behavioral therapy and lifestyle changes, ideally in the same practice ^[2]. Drugs should be started at low doses and titrated gradually, with structured follow-up ^[2]. If goals are not met, options include raising the dose, switching, combining medications, intensifying lifestyle management, or considering bariatric surgery ^[2]. The authors note low-dose combination therapy has produced greater weight reduction than high-dose single-drug therapy in several randomized trials ^[3].

Other points: use of non-FDA-approved compounded products is not recommended, and the guideline offers guidance for switching to another FDA-approved obesity medication if a drug is unavailable ^[1]. All approved obesity medications are contraindicated in pregnancy and in people actively trying to conceive; the guideline suggests stopping at least two months before a planned pregnancy, with lifestyle therapy intensified instead ^[2][3]. Topiramate is specifically linked to major congenital malformations ^[3]. Because these drugs suppress appetite, the standards call for regular nutrition counseling and monitoring, with attention to protein and micronutrient intake and muscle loss risk ^[1][2].

The guideline also lists weight-promoting medications and alternatives — for example, replacing atenolol, metoprolol, propranolol, or alpha-blockers with ACE inhibitors, ARBs, thiazide-like diuretics, carvedilol, or nebivolol — while cautioning that necessary treatments should not be withheld ^[2][3].

Why it matters for patients

Guidelines like this shape what clinicians document and what insurers see. Language saying medication should be offered as part of an initial plan, rather than as a last resort, gives prescribers a citable basis for starting treatment earlier ^[1][2]. The condition-based table also explains why two people with similar weights may be steered toward different drugs: someone with sleep apnea and someone with established cardiovascular disease are pointed to different evidence ^[2].

The tiered targets matter too. A 5% loss is framed as meaningful, but people with complications are held to higher thresholds, which affects whether a drug is judged to be working at a three-month check-in ^[2]. The explicit statement against compounded products, plus guidance on switching during shortages, addresses two issues many US patients have faced directly ^[1].

What happens next

This is the second part of the standards; part one covered weight stigma and bias ^[2]. Full details on mechanisms, dosing, and service organization are in the complete guideline document ^[2]. The timing of additional sections is not stated in these sources.